| __timestamp | Blueprint Medicines Corporation | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 612613000000 |
| Thursday, January 1, 2015 | 14456000 | 650773000000 |
| Friday, January 1, 2016 | 19218000 | 619061000000 |
| Sunday, January 1, 2017 | 27986000 | 628106000000 |
| Monday, January 1, 2018 | 47928000 | 717599000000 |
| Tuesday, January 1, 2019 | 96388000 | 964737000000 |
| Wednesday, January 1, 2020 | 157743000 | 875663000000 |
| Friday, January 1, 2021 | 195293000 | 886361000000 |
| Saturday, January 1, 2022 | 237374000 | 997309000000 |
| Sunday, January 1, 2023 | 295141000 | 1053819000000 |
| Monday, January 1, 2024 | 359272000 | 1053819000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Blueprint Medicines Corporation, a rising star, offer a fascinating study in contrasts. Over the past decade, Takeda's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of Blueprint Medicines, reflecting its expansive global operations. In 2023, Takeda's SG&A expenses reached a staggering 1.05 trillion yen, marking a 72% increase since 2014. Meanwhile, Blueprint Medicines, with its focused approach, saw its SG&A expenses grow by 3,640% over the same period, reaching 295 million yen in 2023. This dramatic rise underscores Blueprint's aggressive expansion and investment in innovation. The data reveals a compelling narrative of growth and strategy, highlighting the diverse paths these companies take in the ever-evolving pharmaceutical industry.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Takeda Pharmaceutical Company Limited
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.